AzTrials
AzTrials

Prostate CancerIRONMANNCT03151629

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

An observational study of Prostate Cancer, run by Prostate Cancer Clinical Trials Consortium at 121 sites in 15 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. Read more about this study

Who is it for?
Ages 21 years and older, men only
Conditions the study is for
Prostate Cancer
How many people
5,000 participants
Where
121 sitesin 15 countries
Study dates
21 Jul 2017to Jan 2032
How long will I take part?
5 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Study population: Metastatic hormone sensitive prostate cancer (mHSPC): Prostate cancer patients diagnosed with histologically confirmed cancer with radiological evidence of metastatic disease and on ADT for no more than 90 days. Castration resistant prostate cancer (CRPC): Prostate cancer patients (with or without radiological evidence of metastatic disease) with a confirmed rising PSA (at least two measures) while on ADT or orchiectomy or castrate level of testosterone as determined by investigator. Prostate cancer patients with mixed histological types may participate in this Registry.

  • Willing and able to provide written informed consent and privacy authorization for the release of personal health information.

NOTE: Privacy authorization may be either included in the informed consent or obtained separately.

  • Males 21 years of age and above
  • Histological or cytological confirmed prostate adenocarcinoma from TRUS biopsy, radical prostatectomy or TURP Or Documented histopathology or cytopathology of prostate adenocarcinoma from a biopsy of a metastatic site Or Metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes) AND a serum concentration of PSA >20ng/mL at the time of initial prostate cancer diagnosis
  • No previous diagnosis of a second, non-prostate malignancy that requires additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin

Trial locations and contacts

121 sites in 15 countries. Contact the study team or a site near you to ask about taking part.

Jacob Vinson contact

646-888-0421

pcctcironmanregistry@mskcc.org

121 sites in 15 countries

United States48 sites, 35 recruiting

  • University of Michigan

    Ann Arbor, Michigan, 48109

    Terminated

  • Morehouse School of Medicine

    Atlanta, Georgia, 30310

    James Lillard, PhD, jlillard@msm.edu

    James Lillard, PhD

    Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia, 30322

    Mehmet Bilen, MD

    Mehmet Bilen, MD

    Recruiting

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21231

    Mark Markowski, mmarko12@jhmi.edu

    Recruiting

  • University of Alabama-Birmingham

    Birmingham, Alabama, 35233

    Completed

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215

    Mark Pomerantz, mark_pomerantz@dfci.harvard.edu

    Recruiting

  • NewYork-Presbyterian Brooklyn Methodist Hospital

    Brooklyn, New York, 11215

    Scott Tagawa, MD, stt2007@med.cornell.edu

    Scott Tagawa, MD

    Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14203

    Active, not recruiting

  • VA Western New York Healthcare System

    Buffalo, New York, 14215

    Terminated

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27514

    Young Whang, young_whang@med.unc.edu

    Recruiting

  • Ralph H. Johnson VA Medical Center

    Charleston, South Carolina, 29401

    Stephen Savage, MD, savages@musc.edu

    Stephen Savage, MD

    Recruiting

  • University of Virginia

    Charlottesville, Virginia, 22903

    Robert Dreicer, rd7va@hscmail.mcc.virginia.edu

    Recruiting

  • University of Illinois at Chicago

    Chicago, Illinois, 60607

    Daniel Moreira, MD, moreira@uic.edu

    Daniel Moreira, MD

    Recruiting

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois, 60611

    David Vanderweele, MD, david.vanderweele@northwestern.edu

    David Vanderweele, MD

    Recruiting

  • University of Chicago

    Chicago, Illinois, 60637

    Russell Szmulewitz, rszmulew@medicine.bsd.uchicago.edu

    Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106

    Pedro Barata, MD, pedro.barata@uhhospitals.org

    Pedro Barata, MD

    Recruiting

  • William Jennings Bryan Dorn VAMC

    Columbia, South Carolina, 29209

    Terminated

  • Kishwaukee Cancer Center

    DeKalb, Illinois, 60115

    Christopher George, MD, christopher.george@nm.org

    Christopher George, MD

    Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201

    Frank Cackowski, MD, cackowskif@karmanos.org

    Recruiting

  • Doylestown Health

    Doylestown, Pennsylvania, 18901

    Completed

  • Durham VA Medical Center

    Durham, North Carolina, 27705

    Rhonda Bitting, MD, Rhonda.Bitting@va.gov

    Rhonda Bitting, MD

    Recruiting

  • Duke Cancer Network

    Durham, North Carolina, 27710

    Tian Zhang, MD

    Tian Zhang, MD

    Recruiting

  • Duke University

    Durham, North Carolina, 27710

    Dan George, daniel.george@duke.edu

    Recruiting

  • University of Florida

    Gainesville, Florida, 32611

    Terminated

  • Delnor Cancer Center

    Geneva, Illinois, 60134

    Christopher George, MD, christopher.george@nm.org

    Christopher George, MD

    Recruiting

  • Baylor College of Medicine

    Houston, Texas, 77030

    Completed

  • University of Mississippi Medical Center

    Jackson, Mississippi, 39216

    John Henegan, MD, jhenegan@umc.edu

    John Henegan, MD

    Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224

    Folakemi Odedina, PhD, Odedina.Folakemi@mayo.edu

    Folakemi Odedina, PhD

    Recruiting

  • University of California - Los Angeles

    Los Angeles, California, 90024

    Terminated

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin, 53705

    Hamid Emamekhoo, MD

    Hamid Emamekhoo, MD

    Recruiting

  • Memphis VA Medical Center

    Memphis, Tennessee, 38104

    Alva Weir, MD, Alva.weir@va.gov

    Recruiting

  • Baptist Clinical Research Institute

    Memphis, Tennessee, 38120

    Osarenren Ogbeide, MD, osa.ogbeide@bmg.md

    Osarenren Ogbeide, MD

    Recruiting

  • Yale University

    New Haven, Connecticut, 06502

    Daniel Petrylak, MD, daniel.petrylak@yale.edu

    Daniel Petrylak, MD

    Recruiting

  • Tulane University

    New Orleans, Louisiana, 70118

    Active, not recruiting

  • Columbia University Medical Center

    New York, New York, 10032

    Mark Stein, MD

    Mark Stein, MD

    Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065

    Karen Autio, MD, autiok@mskcc.org

    Recruiting

  • Weill Cornell Medical Center

    New York, New York, 10065

    Scott Tagawa, MD

    Scott Tagawa, MD

    Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107

    Active, not recruiting

  • Fox Chase Cancer Center - Temple Health

    Philadelphia, Pennsylvania, 19134

    Camille Ragin, PhD, Camille.Ragin@fccc.edu

    Camille Ragin, PhD

    Recruiting

  • Oregon Health & Science University Hospital

    Portland, Oregon, 97239

    Alexandra Sokolova, sokolova@ohsu.edu

    Sokolova

    Recruiting

  • University of California San Diego

    San Diego, California, 92037

    Rana McKay, MD

    Rana McKay, MD

    Recruiting

  • University of Washington Medical Center

    Seattle, Washington, 98195

    Active, not recruiting

  • Moffitt Cancer Center

    Tampa, Florida, 33612

    Monica Chatwal, MD, Monica.chatwal@moffitt.org

    Recruiting

  • Chesapeake Urology Associates

    Towson, Maryland, 21204

    Terminated

  • University of Alabama- Tuscaloosa

    Tuscaloosa, Alabama, 35487

    Camille Ragin, camille.ragin@fccc.edu

    Camille Ragin, PhD

    Recruiting

  • Warrenville Cancer Center

    Warrenville, Illinois, 60555

    Christopher George, MD, christopher.george@nm.org

    Christopher George, MD

    Recruiting

  • Reading Health System

    West Reading, Pennsylvania, 19611

    Terrence Cescon, MD, Terrence.cescon@towerhealth.org

    Terrence Cescon, MD

    Recruiting

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts, 01655

    Kriti Mittal, MD

    Kriti Mittal, MD

    Recruiting

Other trials in United States

United Kingdom13 sites, 11 recruiting

  • Velindre Cancer Centre

    Cardiff

    Jacob Tanguay, MD, Jacob.Tanguay@wales.nhs.uk

    Jacob Tanguay, MD

    Recruiting

  • University Hospitals of Morecambe Bay NHS Foundation Trust

    Lancaster

    Alison Birtle, MD, Alison.Birtle@mbht.nhs.uk

    Alison Birtle, MD

    Recruiting

  • Guys St Thomas NHS Foundation Trust

    London

    Harriet Wylie, harriet.wylie@kcl.ac.uk

    Deborah Enting

    Recruiting

  • The Royal Marsden NHS Foundation Trust

    London

    Vincent Khoo, vincent.khoo@rmh.nhs.uk

    Vincent Khoo, MD

    Recruiting

  • The Christie NHS Foundation Trust

    Manchester

    Ananya Choudhury, Ananya.Choudhury@christie.nhs.uk

    Recruiting

  • Clatterbridge Cancer Centre

    Metropolitan Borough of Wirral

    Isabel Syndikus, MD, isabel.syndikus@nhs.net

    Isabel Syndikus, MD

    Recruiting

  • Mount Vernon Cancer Centre

    Northwood, Middlesex, HA6 2RN

    Anand Sharma, MD, anand.sharma3@nhs.net

    Anand Sharma, MD

    Recruiting

  • Lancashire Teaching Hospitals NHS Foundation Trust

    Preston, PR2 9HT

    Alison Birtle, MD, Alison.Birtle@lthtr.nhs.uk

    Alison Birtle, MD

    Recruiting

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, S10 2SB

    Carmel Pezaro, MD, carmel.pezaro@nhs.net

    Carmel Pezaro, MD

    Recruiting

  • South Tyneside District Hospital

    South Shields, NE34 0PL

    Terminated

  • University Hospital Southampton NHS Foundation Trust

    Southampton, Hampshire

    Simon Crabb, MD, simon.crabb@uhs.nhs.uk

    Simon Crabb, MD

    Recruiting

  • Lister Hospital

    Stevenage, Hertfordshire, SG1 4AB

    Anand Sharma, MD, anand.sharma3@nhs.net

    Anand Sharma, MD

    Recruiting

  • Sunderland Royal Hospital

    Sunderland, SR4 7TP

    Terminated

Other trials in United Kingdom

Spain12 sites

  • Institut Catalá d'Oncologia Badalona

    Badalona

    Active, not recruiting

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona

    Active, not recruiting

  • Vall d'Hebron Institute of Oncology

    Barcelona, Catalonia

    Active, not recruiting

  • Fundació Institut Mar d'Investigacions Mèdiques (Hospital del Mar).

    Barcelona

    Active, not recruiting

  • Hospital Provincial de Castellón

    Castellon

    Active, not recruiting

  • Hospital Universitario La Princesa

    Madrid, 28006

    Active, not recruiting

  • Hospital Clinico San Carlos

    Madrid

    Active, not recruiting

  • Hospital Universitario 12 de Octubre

    Madrid

    Active, not recruiting

  • Hospital Universitario Virgen de la Victoria

    Málaga, Málaga

    Active, not recruiting

  • Hospital Universitario Central de Asturias

    Oviedo, 33011

    Active, not recruiting

  • Instituto Valenciano de Oncología

    Valencia, Valencia, 46009

    Active, not recruiting

  • Hospital Universitario Miguel Servet (Zaragoza)

    Zaragoza

    Active, not recruiting

Other trials in Spain

Australia11 sites, 11 recruiting

  • Eastern Health (Box Hill Hospital)

    Box Hill, Victoria

    Ian Davis

    Ian Davis

    Recruiting

  • Redland Hospital

    Cleveland, Queensland

    Ian Vela

    Ian Vela

    Recruiting

  • St. Vincent's Hospital Sydney

    Darlinghurst, New South Wales

    Anthony Joshua, MD, Anthony.Joshua@svha.org.au

    Anthony Joshua, MD

    Recruiting

  • Royal Brisbane & Women's Hospital

    Herston, Brisbane

    Ian D Davis, MD, Ian.davis@monash.edu

    Ian D Davis, MD

    Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000

    Declan Murphy, MD, Declan.Murphy@petermac.org

    Declan Murphy

    Recruiting

  • Australian Urology Associates

    Melbourne

    Mark Frydenberg

    Mark Frydenberg

    Recruiting

  • Australian Prostate Centre

    Melbourne N.

    Philip Dundee, MD, phildundee@gmail.com

    Philip Dundee, MD

    Recruiting

  • Epworth Healthcare

    Mount Waverley, Victoria, 3149

    Ben Tran, MD, ben.tran@petermac.org

    Ben Tran, MD

    Recruiting

  • Macquarie University

    Sydney, New South Wales

    Howard Gurney

    Howard Gurney

    Recruiting

  • Westmead Hospital

    Sydney, New South Wales

    Howard Gurney

    Howard Gurney

    Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland

    Ian Vela

    Ian Vela

    Recruiting

Other trials in Australia

Canada7 sites, 7 recruiting

  • Cross Cancer Institute (Alberta Health Services)

    Edmonton, Alberta, T6G 1Z2

    Michael Kolinsky, MD, Michael.Kolinsky@ahs.ca

    Michael Kolinsky, MD

    Recruiting

  • Juravinski Cancer Centre

    Hamilton, Ontario

    Sebastian Hotte

    Sebastian Hotte

    Recruiting

  • Centre hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec

    Fred Saad

    Fred Saad

    Recruiting

  • Ottawa Hospital Cancer Centre

    Ottawa, Ontario

    Michael Ong

    Michael Ong

    Recruiting

  • CHU de Québec-Université Laval

    Québec, Quebec

    Frederic Pouliot

    Frederic Pouliot

    Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2C1

    Antonio Finelli, MD, Antonio.finelli@uhn.ca

    Antonio Finelli, MD

    Recruiting

  • BC Cancer Agency

    Vancouver, British Columbia

    Kim Chi

    Kim Chi

    Recruiting

Other trials in Canada

Brazil6 sites

  • Hospital Beneficência Portuguesa

    Bela Vista, São Paulo

    Terminated

  • Tacchini Hospital

    Bento Gonçalves, Rio Grande do Sul, 95700-084

    Active, not recruiting

  • Instituto do Câncer e Transplante

    Curitiba

    Completed

  • Centro de Pesquisa em Oncologia

    Porto Alegre

    Active, not recruiting

  • Centro Paulista de Oncologia

    São Paulo

    Completed

  • Instituto Câncer do Estado de São Paulo

    São Paulo

    Completed

Other trials in Brazil

Switzerland6 sites

  • Universitätsspital Basel

    Basel

    Active, not recruiting

  • Ente Ospedaliero Cantonale

    Bellinzona, Bellinzona, 6500

    Active, not recruiting

  • Kantonsspital Graubünden

    Chur

    Active, not recruiting

  • Kantonsspital St. Gallen

    Sankt Gallen

    Active, not recruiting

  • Onkozentrum Zürich

    Zurich, 8039

    Active, not recruiting

  • Universitätsspital Zürich

    Zurich

    Active, not recruiting

Other trials in Switzerland

Ireland4 sites, 4 recruiting

  • Beacon Hospital

    Dublin, Leinster

    Ray McDermott

    Ray McDermott

    Recruiting

  • Tallaght University Hospital

    Dublin, D24 NR0A

    Ray McDermott, MD, Ray.McDermott@tuh.ie

    Ray McDermott, MD

    Recruiting

  • St. Vincent's University Hospital

    Dublin

    Ray McDermott, MD, Ray.McDermott@tuh.ie

    Ray McDermott, MD

    Recruiting

  • Sligo University Hospital

    Sligo, F91 H684

    Ala Yousif, MD, Ala.yousif@hse.ie

    Ala Yousif, MD

    Recruiting

Other trials in Ireland

Nigeria4 sites

  • Federal Medical Centre Abeokuta

    Abeokuta

    Active, not recruiting

  • University of Ilorin Teaching Hospital

    Ilorin

    Active, not recruiting

  • Lagos State University Teaching Hospital

    Lagos

    Active, not recruiting

  • University of Maiduguri Teaching Hospital

    Maiduguri

    Active, not recruiting

Other trials in Nigeria

South Africa3 sites

  • Groote Schuur Hospital

    Cape Town, 7925

    Active, not recruiting

  • The Medical Oncology Centre of Rosebank

    Johannesburg, Gauteng, 2196

    Active, not recruiting

  • Steve Biko Academic Hospital

    Pretoria, Gauteng, 0084

    Active, not recruiting

Other trials in South Africa

Sweden3 sites, 3 recruiting

  • Skane University Hospital

    Malmö, Skåne County

    Anders Bjartell

    Anders Bjartell

    Recruiting

  • Orebro University Hospital

    Örebro

    Janus Frey, janusz.frey@regionorebrolan.se;

    Recruiting

  • Umea University Hospital

    Umeå, Sweden, 907 37

    Camilla karlsson, MD, camilla.thellenberg@umu.se

    Camilla karlsson, MD

    Recruiting

Other trials in Sweden

Barbados1 site, 1 recruiting

  • The University of the West Indies - Cave Hill Campus

    Bridgetown

    Simon Anderson, MBBCh, simon.anderson@cavehill.uwi.edu

    Simon Anderson, MBBCh

    Recruiting
Jamaica1 site, 1 recruiting

  • The University of the West Indies - Mona Campus

    Kingston

    Simone Badal, PhD, simone.badal@uwimona.edu.jm

    Simone Badal, PhD

    Recruiting

Other trials in Jamaica

Kenya1 site, 1 recruiting

  • University of Nairobi

    Nairobi

    Charles G Waihenya, MBChB, charleswaihenya@uonbi.ac.ke

    Charles G Waihenya, MBChB

    Recruiting

Other trials in Kenya

Norway1 site, 1 recruiting

  • Oslo University Hospital

    Oslo, 0379

    Kjell Russnes, MD, KMF@ous-hf.no

    Kjell Russnes, MD

    Recruiting

Other trials in Norway

About this study

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices.

Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs.

Read more

PROMs questionnaires will be collected at enrollment and every three months thereafter.

Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment.

As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.

Conditions
Prostate Cancer
Being tested
Standard of Care
Medical subject headings
Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standard of CareOther

    Drugs routinely administered for metastatic prostate cancer per local standard.

Study groups in NCT03151629
Study groupRoleWhat they receive
Castrate Resistant Prostate CancerNot described
Receives: Other: Standard of Care
Hormone Sensitive Prostate CancerNot described
Receives: Other: Standard of Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Practice Patterns

    To describe the practice patterns of therapeutic agents for treatment of advanced prostate cancer internationally

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 May 2017
  2. Study start21 Jul 2017
  3. Primary completionJan 2031 (estimated)
  4. Study completionJan 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
5,000 participants (estimated)
Target duration
5 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT03151629
Sponsor's protocol ID
c16-170
Acronym
IRONMAN
Status last verified
May 2026
First submitted
10 May 2017
Last updated
22 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Rencsok EM, Slopen N, McManus HD, Autio KA, Morgans AK, McSwain L, Barata P, Cheng HH, Dreicer R, Gerke T, Green R, Heath EI, Howard LE, McKay RR, Nowak J, Pileggi S, Pomerantz MM, Rathkopf DE, Tagawa ST, Whang YE, Ragin C, Odedina FT, Kantoff PW, Vinson J, Villanti P, Haneuse S, Mucci LA, George DJ; IRONMAN Registry. Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States. Cancer Res Commun. 2024 Jan 8;4(1):55-64. doi: 10.1158/2767-9764.CRC-23-0446.

    PubMed 38108490

  • Rencsok EM, Stopsack KH, Slopen N, Odedina FT, Ragin C, Nowak J, McSwain L, Manarite J, Heath E, George DJ, Kantoff PW, Vinson J, Villanti P, Haneuse S, Mucci LA; IRONMAN Registry. Experience with the US health care system for Black and White patients with advanced prostate cancer. Cancer. 2023 Aug 15;129(16):2532-2541. doi: 10.1002/cncr.34885. Epub 2023 May 28.

    PubMed 37246339

  • McKay RR, Gold T, Zarif JC, Chowdhury-Paulino IM, Friedant A, Gerke T, Grant M, Hawthorne K, Heath E, Huang FW, Jackson MD, Mahal B, Ogbeide O, Paich K, Ragin C, Rencsok EM, Simmons S, Yates C, Vinson J, Kantoff PW, George DJ, Mucci LA. Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. JCO Glob Oncol. 2021 Apr;7:495-505. doi: 10.1200/GO.20.00571.

    PubMed 33835826

Questions about this trial

What is this clinical trial studying?

An observational study of Prostate Cancer, run by Prostate Cancer Clinical Trials Consortium at 121 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 121 sites in United States, United Kingdom, Spain, Australia, Canada and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jacob Vinson (646-888-0421, pcctcironmanregistry@mskcc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Practice Patterns (time frame: 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03151629, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in